Baidu
map

住院成人高血糖患者血糖监测医护协议处方共识

2019-08-30 中华护理学会糖尿病护理专业委员会 中华护理杂志.2019.54(8):1142-1147.

为加强院内血糖监测与护理的同质化、规范化管理,中华护理学会糖尿病专业委员会联合内分泌科医疗专家,结合我国实际,依据最新的循证医学证据,在2017年《高血糖患者围手术期血糖护理工作指引》的基础上,制订了《住院成人高血糖患者血糖监测医护协议处方共识》(以下简称《处方共识》),在医生与护士共同协议的前提下,制订系统的监测方案与流程,避免盲目无序的血糖监测,以提升临床血糖管理质量,提高患者满意度。

中文标题:

住院成人高血糖患者血糖监测医护协议处方共识

发布日期:

2019-08-30

简要介绍:

为加强院内血糖监测与护理的同质化、规范化管理,中华护理学会糖尿病专业委员会联合内分泌科医疗专家,结合我国实际,依据最新的循证医学证据,在2017年《高血糖患者围手术期血糖护理工作指引》的基础上,制订了《住院成人高血糖患者血糖监测医护协议处方共识》(以下简称《处方共识》),在医生与护士共同协议的前提下,制订系统的监测方案与流程,避免盲目无序的血糖监测,以提升临床血糖管理质量,提高患者满意度。

 

拓展指南:血糖相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=住院成人高血糖患者血糖监测医护协议处方共识)] GetToolGuiderByIdResponse(projectId=1, id=efbac1c001811277, title=住院成人高血糖患者血糖监测医护协议处方共识, enTitle=, guiderFrom=中华护理杂志.2019.54(8):1142-1147., authorId=null, author=, summary=为加强院内血糖监测与护理的同质化、规范化管理,中华护理学会糖尿病专业委员会联合内分泌科医疗专家,结合我国实际,依据最新的循证医学证据,在2017年《高血糖患者围手术期血糖护理工作指引》的基础上,制订了《住院成人高血糖患者血糖监测医护协议处方共识》(以下简称《处方共识》),在医生与护士共同协议的前提下,制订系统的监测方案与流程,避免盲目无序的血糖监测,以提升临床血糖管理质量,提高患者满意度。 , cover=, journalId=null, articlesId=null, associationId=1838, associationName=中华护理学会糖尿病护理专业委员会, associationIntro= 中华护理学会糖尿病护理专业委员会, copyright=0, guiderPublishedTime=Fri Aug 30 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<P>为加强院内血糖监测与护理的同质化、规范化管理,中华护理学会糖尿病专业委员会联合内分泌科医疗专家,结合我国实际,依据最新的循证医学证据,在2017年《高血糖患者围手术期血糖护理工作指引》的基础上,制订了《住院成人高血糖患者血糖监测医护协议处方共识》(以下简称《处方共识》),在医生与护士共同协议的前提下,制订系统的监测方案与流程,避免盲目无序的血糖监测,以提升临床血糖管理质量,提高患者满意度。 </P> <P> </P>拓展指南:<STRONG>与<FONT color=red>血糖</FONT>相关指南:</STRONG><BR> <UL> <LI><A title="2019 昆士兰临床指南:新生儿低血糖" target=_blank href="//m.sandwebs.com/guideline/show_article.do?id=0c4331c00180e5a1">2019 昆士兰临床指南:新生儿低血糖</A> <LI><A title="2019 南亚工作组共识建议:应用胰高血糖素样肽-1受体激动剂 (GLP-1 RAs)治疗2型糖尿病" target=_blank href="//m.sandwebs.com/guideline/show_article.do?id=43d5d1c001e751f0">2019 南亚工作组共识建议:应用胰高血糖素样肽-1受体激动剂 (GLP-1 RAs)治疗2型糖尿病</A> <LI><A title="2018 RACGP/ADS临床立场声明:基层医疗中高血糖紧急情况的管理" target=_blank href="//m.sandwebs.com/guideline/show_article.do?id=d5f6b1c0016628bb">2018 RACGP/ADS临床立场声明:基层医疗中高血糖紧急情况的管理</A> <LI><A title="2018 ADA/EASD共识:2型糖尿病患者高血糖的管理" target=_blank href="//m.sandwebs.com/guideline/show_article.do?id=652da1c0016a8946">2018 ADA/EASD共识:2型糖尿病患者高血糖的管理</A> <LI><A title="2018 AOFOG共识声明:妊娠期高血糖的筛查" target=_blank href="//m.sandwebs.com/guideline/show_article.do?id=8a2ca1c0016a3506">2018 AOFOG共识声明:妊娠期高血糖的筛查</A> 更多信息请点击:<A target=_blank href="//m.sandwebs.com/guideline/list.do?q=%E8%A1%80%E7%B3%96">有关血糖更多指南</A></LI></UL>, tagList=[TagDto(tagId=96114, tagName=成人高血糖), TagDto(tagId=4675, tagName=血糖监测), TagDto(tagId=96115, tagName=医护协议处方)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=8, categoryName=糖尿病, tenant=100), CategoryDto(categoryId=79, categoryName=护理, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=9251, appHits=475, showAppHits=8, pcHits=4830, showPcHits=5672, likes=149, shares=33, comments=20, approvalStatus=1, publishedTime=Wed Oct 30 00:36:41 CST 2019, publishedTimeString=2019-08-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Wed Oct 30 00:36:41 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 13:38:18 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=住院成人高血糖患者血糖监测医护协议处方共识)])
住院成人高血糖患者血糖监测医护协议处方共识
下载请点击:
评论区 (18)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1206038, encodeId=2cf4120603804, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6dae4838671, createdName=1441fef2m15暂无昵称, createdTime=Sat Mar 26 08:34:52 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194655, encodeId=3f6e1194655a6, content=看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=066c2128345, createdName=1351fc2f66m, createdTime=Fri Feb 18 00:47:06 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052094, encodeId=3e721052094de, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210916/ca18fa43b42c40c8be92bbcee1c176a0/b6ae54edd2cb4f3792daf7c8a4b83595.jpg, createdBy=68385608510, createdName=ms9000000104142834, createdTime=Thu Sep 16 21:28:11 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008770, encodeId=36b11008e7032, content=我想要积分积分积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230508/c2573541a6524ff0944d5799c7cc7568/264cbd4dbc3541b89cf280191fc834d7.jpg, createdBy=29e92023744, createdName=doufangyan, createdTime=Tue Aug 17 17:21:27 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003128, encodeId=19f010031283e, content=好资料 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fb85527721, createdName=ms2000000352050289, createdTime=Tue Jul 27 20:58:39 CST 2021, time=2021-07-27, status=1, ipAttribution=)]
    2022-03-26 1441fef2m15暂无昵称

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1206038, encodeId=2cf4120603804, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6dae4838671, createdName=1441fef2m15暂无昵称, createdTime=Sat Mar 26 08:34:52 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194655, encodeId=3f6e1194655a6, content=看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=066c2128345, createdName=1351fc2f66m, createdTime=Fri Feb 18 00:47:06 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052094, encodeId=3e721052094de, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210916/ca18fa43b42c40c8be92bbcee1c176a0/b6ae54edd2cb4f3792daf7c8a4b83595.jpg, createdBy=68385608510, createdName=ms9000000104142834, createdTime=Thu Sep 16 21:28:11 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008770, encodeId=36b11008e7032, content=我想要积分积分积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230508/c2573541a6524ff0944d5799c7cc7568/264cbd4dbc3541b89cf280191fc834d7.jpg, createdBy=29e92023744, createdName=doufangyan, createdTime=Tue Aug 17 17:21:27 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003128, encodeId=19f010031283e, content=好资料 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fb85527721, createdName=ms2000000352050289, createdTime=Tue Jul 27 20:58:39 CST 2021, time=2021-07-27, status=1, ipAttribution=)]
    2022-02-18 1351fc2f66m

    看看

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1206038, encodeId=2cf4120603804, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6dae4838671, createdName=1441fef2m15暂无昵称, createdTime=Sat Mar 26 08:34:52 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194655, encodeId=3f6e1194655a6, content=看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=066c2128345, createdName=1351fc2f66m, createdTime=Fri Feb 18 00:47:06 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052094, encodeId=3e721052094de, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210916/ca18fa43b42c40c8be92bbcee1c176a0/b6ae54edd2cb4f3792daf7c8a4b83595.jpg, createdBy=68385608510, createdName=ms9000000104142834, createdTime=Thu Sep 16 21:28:11 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008770, encodeId=36b11008e7032, content=我想要积分积分积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230508/c2573541a6524ff0944d5799c7cc7568/264cbd4dbc3541b89cf280191fc834d7.jpg, createdBy=29e92023744, createdName=doufangyan, createdTime=Tue Aug 17 17:21:27 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003128, encodeId=19f010031283e, content=好资料 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fb85527721, createdName=ms2000000352050289, createdTime=Tue Jul 27 20:58:39 CST 2021, time=2021-07-27, status=1, ipAttribution=)]
    2021-09-16 ms9000000104142834

    积分

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1206038, encodeId=2cf4120603804, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6dae4838671, createdName=1441fef2m15暂无昵称, createdTime=Sat Mar 26 08:34:52 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194655, encodeId=3f6e1194655a6, content=看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=066c2128345, createdName=1351fc2f66m, createdTime=Fri Feb 18 00:47:06 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052094, encodeId=3e721052094de, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210916/ca18fa43b42c40c8be92bbcee1c176a0/b6ae54edd2cb4f3792daf7c8a4b83595.jpg, createdBy=68385608510, createdName=ms9000000104142834, createdTime=Thu Sep 16 21:28:11 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008770, encodeId=36b11008e7032, content=我想要积分积分积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230508/c2573541a6524ff0944d5799c7cc7568/264cbd4dbc3541b89cf280191fc834d7.jpg, createdBy=29e92023744, createdName=doufangyan, createdTime=Tue Aug 17 17:21:27 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003128, encodeId=19f010031283e, content=好资料 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fb85527721, createdName=ms2000000352050289, createdTime=Tue Jul 27 20:58:39 CST 2021, time=2021-07-27, status=1, ipAttribution=)]
    2021-08-17 doufangyan

    我想要积分积分积分

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1206038, encodeId=2cf4120603804, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6dae4838671, createdName=1441fef2m15暂无昵称, createdTime=Sat Mar 26 08:34:52 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194655, encodeId=3f6e1194655a6, content=看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=066c2128345, createdName=1351fc2f66m, createdTime=Fri Feb 18 00:47:06 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052094, encodeId=3e721052094de, content=积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210916/ca18fa43b42c40c8be92bbcee1c176a0/b6ae54edd2cb4f3792daf7c8a4b83595.jpg, createdBy=68385608510, createdName=ms9000000104142834, createdTime=Thu Sep 16 21:28:11 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008770, encodeId=36b11008e7032, content=我想要积分积分积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230508/c2573541a6524ff0944d5799c7cc7568/264cbd4dbc3541b89cf280191fc834d7.jpg, createdBy=29e92023744, createdName=doufangyan, createdTime=Tue Aug 17 17:21:27 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003128, encodeId=19f010031283e, content=好资料 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8fb85527721, createdName=ms2000000352050289, createdTime=Tue Jul 27 20:58:39 CST 2021, time=2021-07-27, status=1, ipAttribution=)]
    2021-07-27 ms2000000352050289

    好资料

    0

Baidu
map
Baidu
map
Baidu
map